EE10 Cost-Effectiveness of Pembrolizumab Plus Chemotherapies for First-Line Treatment in Locally Advanced Unresectable or Metastatic Triple Negative Breast Cancer (MTNBC) in France
Dec 1, 2022, 00:00 AM
10.1016/j.jval.2022.09.264
https://www.valueinhealthjournal.com/article/S1098-3015(22)02468-8/fulltext
Section Title :
Section Order :
12066
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)02468-8&doi=10.1016/j.jval.2022.09.264